COvid MEdicaTion (COMET) study: protocol for a cohort study.
Identifieur interne : 000108 ( Main/Curation ); précédent : 000107; suivant : 000109COvid MEdicaTion (COMET) study: protocol for a cohort study.
Auteurs : Roos S G. Sablerolles [Pays-Bas] ; Freija E F. Hogenhuis [Pays-Bas] ; Melvin Lafeber [Pays-Bas] ; Bob P A. Van De Loo [Pays-Bas] ; Sander D. Borgsteede [Pays-Bas] ; Eric Boersma [Pays-Bas] ; Jorie Versmissen [Pays-Bas] ; Hugo M. Van Der Kuy [Pays-Bas]Source :
- European journal of hospital pharmacy : science and practice [ 2047-9956 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antagonistes du récepteur de type 1 de l'angiotensine-II (usage thérapeutique), Bases de données factuelles (MeSH), Essais contrôlés randomisés comme sujet (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Mâle (MeSH), Pandémies (MeSH), Peptidyl-Dipeptidase A (usage thérapeutique), Plan de recherche (MeSH), Pneumopathie virale (traitement médicamenteux), Protocoles cliniques (MeSH), Protéines recombinantes (usage thérapeutique), Résultat thérapeutique (MeSH), Études de cohortes (MeSH).
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antagonistes du récepteur de type 1 de l'angiotensine-II, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Peptidyl-Dipeptidase A, Protéines recombinantes.
- Animaux, Bases de données factuelles, Essais contrôlés randomisés comme sujet, Femelle, Humains, Mâle, Pandémies, Plan de recherche, Protocoles cliniques, Résultat thérapeutique, Études de cohortes.
English descriptors
- KwdEn :
- Angiotensin II Type 1 Receptor Blockers (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Animals (MeSH), Clinical Protocols (MeSH), Cohort Studies (MeSH), Coronavirus Infections (drug therapy), Databases, Factual (MeSH), Female (MeSH), Humans (MeSH), Male (MeSH), Pandemics (MeSH), Peptidyl-Dipeptidase A (therapeutic use), Pneumonia, Viral (drug therapy), Randomized Controlled Trials as Topic (MeSH), Recombinant Proteins (therapeutic use), Research Design (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A, Recombinant Proteins.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Animals, Clinical Protocols, Cohort Studies, Databases, Factual, Female, Humans, Male, Pandemics, Randomized Controlled Trials as Topic, Research Design, Treatment Outcome.
Abstract
Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
DOI: 10.1136/ejhpharm-2020-002329
PubMed: 32587077
PubMed Central: PMC7335622
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000108
Links to Exploration step
pubmed:32587077Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COvid MEdicaTion (COMET) study: protocol for a cohort study.</title><author><name sortKey="Sablerolles, Roos S G" sort="Sablerolles, Roos S G" uniqKey="Sablerolles R" first="Roos S G" last="Sablerolles">Roos S G. Sablerolles</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Hogenhuis, Freija E F" sort="Hogenhuis, Freija E F" uniqKey="Hogenhuis F" first="Freija E F" last="Hogenhuis">Freija E F. Hogenhuis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lafeber, Melvin" sort="Lafeber, Melvin" uniqKey="Lafeber M" first="Melvin" last="Lafeber">Melvin Lafeber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van De Loo, Bob P A" sort="Van De Loo, Bob P A" uniqKey="Van De Loo B" first="Bob P A" last="Van De Loo">Bob P A. Van De Loo</name><affiliation wicri:level="1"><nlm:affiliation>Digitalis Rx BV, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Digitalis Rx BV, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Borgsteede, Sander D" sort="Borgsteede, Sander D" uniqKey="Borgsteede S" first="Sander D" last="Borgsteede">Sander D. Borgsteede</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Decision Support, Health Base Foundation, Houten, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Clinical Decision Support, Health Base Foundation, Houten, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Boersma, Eric" sort="Boersma, Eric" uniqKey="Boersma E" first="Eric" last="Boersma">Eric Boersma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cardiology, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Versmissen, Jorie" sort="Versmissen, Jorie" uniqKey="Versmissen J" first="Jorie" last="Versmissen">Jorie Versmissen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Kuy, Hugo M" sort="Van Der Kuy, Hugo M" uniqKey="Van Der Kuy H" first="Hugo M" last="Van Der Kuy">Hugo M. Van Der Kuy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands h.vanderkuy@erasmusmc.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32587077</idno><idno type="pmid">32587077</idno><idno type="doi">10.1136/ejhpharm-2020-002329</idno><idno type="pmc">PMC7335622</idno><idno type="wicri:Area/Main/Corpus">000108</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000108</idno><idno type="wicri:Area/Main/Curation">000108</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000108</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COvid MEdicaTion (COMET) study: protocol for a cohort study.</title><author><name sortKey="Sablerolles, Roos S G" sort="Sablerolles, Roos S G" uniqKey="Sablerolles R" first="Roos S G" last="Sablerolles">Roos S G. Sablerolles</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Hogenhuis, Freija E F" sort="Hogenhuis, Freija E F" uniqKey="Hogenhuis F" first="Freija E F" last="Hogenhuis">Freija E F. Hogenhuis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lafeber, Melvin" sort="Lafeber, Melvin" uniqKey="Lafeber M" first="Melvin" last="Lafeber">Melvin Lafeber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van De Loo, Bob P A" sort="Van De Loo, Bob P A" uniqKey="Van De Loo B" first="Bob P A" last="Van De Loo">Bob P A. Van De Loo</name><affiliation wicri:level="1"><nlm:affiliation>Digitalis Rx BV, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Digitalis Rx BV, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Borgsteede, Sander D" sort="Borgsteede, Sander D" uniqKey="Borgsteede S" first="Sander D" last="Borgsteede">Sander D. Borgsteede</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Decision Support, Health Base Foundation, Houten, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Clinical Decision Support, Health Base Foundation, Houten, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Boersma, Eric" sort="Boersma, Eric" uniqKey="Boersma E" first="Eric" last="Boersma">Eric Boersma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cardiology, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Versmissen, Jorie" sort="Versmissen, Jorie" uniqKey="Versmissen J" first="Jorie" last="Versmissen">Jorie Versmissen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Kuy, Hugo M" sort="Van Der Kuy, Hugo M" uniqKey="Van Der Kuy H" first="Hugo M" last="Van Der Kuy">Hugo M. Van Der Kuy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands h.vanderkuy@erasmusmc.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam</wicri:regionArea></affiliation></author></analytic><series><title level="j">European journal of hospital pharmacy : science and practice</title><idno type="ISSN">2047-9956</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin II Type 1 Receptor Blockers (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Animals (MeSH)</term><term>Clinical Protocols (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Databases, Factual (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Pandemics (MeSH)</term><term>Peptidyl-Dipeptidase A (therapeutic use)</term><term>Pneumonia, Viral (drug therapy)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>Recombinant Proteins (therapeutic use)</term><term>Research Design (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antagonistes du récepteur de type 1 de l'angiotensine-II (usage thérapeutique)</term><term>Bases de données factuelles (MeSH)</term><term>Essais contrôlés randomisés comme sujet (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Peptidyl-Dipeptidase A (usage thérapeutique)</term><term>Plan de recherche (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Protocoles cliniques (MeSH)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Études de cohortes (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II Type 1 Receptor Blockers</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Peptidyl-Dipeptidase A</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes du récepteur de type 1 de l'angiotensine-II</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Peptidyl-Dipeptidase A</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Protocols</term><term>Cohort Studies</term><term>Databases, Factual</term><term>Female</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>Randomized Controlled Trials as Topic</term><term>Research Design</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bases de données factuelles</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Plan de recherche</term><term>Protocoles cliniques</term><term>Résultat thérapeutique</term><term>Études de cohortes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32587077</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2047-9956</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>European journal of hospital pharmacy : science and practice</Title><ISOAbbreviation>Eur J Hosp Pharm</ISOAbbreviation></Journal><ArticleTitle>COvid MEdicaTion (COMET) study: protocol for a cohort study.</ArticleTitle><Pagination><MedlinePgn>191-193</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/ejhpharm-2020-002329</ELocationID><Abstract><AbstractText>Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.</AbstractText><CopyrightInformation>© European Association of Hospital Pharmacists 2020. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Sablerolles</LastName><ForeName>Roos S G</ForeName><Initials>RSG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hogenhuis</LastName><ForeName>Freija E F</ForeName><Initials>FEF</Initials><AffiliationInfo><Affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafeber</LastName><ForeName>Melvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Loo</LastName><ForeName>Bob P A</ForeName><Initials>BPA</Initials><AffiliationInfo><Affiliation>Digitalis Rx BV, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgsteede</LastName><ForeName>Sander D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Clinical Decision Support, Health Base Foundation, Houten, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boersma</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Versmissen</LastName><ForeName>Jorie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0674-7765</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Kuy</LastName><ForeName>Hugo M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0002-7128-8801</Identifier><AffiliationInfo><Affiliation>Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands h.vanderkuy@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COMET Research team</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Hosp Pharm</MedlineTA><NlmUniqueID>101578294</NlmUniqueID><ISSNLinking>2047-9956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adverse effects</Keyword><Keyword MajorTopicYN="Y">clinical pharmacy</Keyword><Keyword MajorTopicYN="Y">hypertension</Keyword><Keyword MajorTopicYN="Y">vascular medicine</Keyword><Keyword MajorTopicYN="Y">virology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Aleman</LastName><ForeName>Jacomien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagele</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stemer</LastName><ForeName>Gunar</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tournoy</LastName><ForeName>Jos</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>derLinden</LastName><ForeName>Lorenz van</ForeName><Initials>LV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krusteva</LastName><ForeName>Irena</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safipour</LastName><ForeName>Zohreh</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bengaard</LastName><ForeName>Anne Kathrine</ForeName><Initials>AK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houlind</LastName><ForeName>Morten Baltzer</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerjean</LastName><ForeName>Nathalie Pons</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grand</LastName><ForeName>Jennifer Le</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zenico</LastName><ForeName>Carito</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berlinghini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caruso</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peverini</LastName><ForeName>Manola</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pieraccini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bini</LastName><ForeName>Katia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Candela</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiCarlo</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grinta</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salaffi</LastName><ForeName>Fausto</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schimizzi</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tardella</LastName><ForeName>Marika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verri</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tessari</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchesini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chessa</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambera</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martignoni</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rametta</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pappalardo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fantini</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maria</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambarelli</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berlinghini</LastName><ForeName>Sivlia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martini</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pagliarino</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loche</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agnoletto</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peverini</LastName><ForeName>Manola</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boni</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Falcao</LastName><ForeName>Margarida</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farinha</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendes</LastName><ForeName>Dina</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rijo</LastName><ForeName>Joao</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmo</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Falcao</LastName><ForeName>Fatima</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soares</LastName><ForeName>Joana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solano</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viegas</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miarons</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>QueraltGorgas</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yubero</LastName><ForeName>Cristina García</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horcajada</LastName><ForeName>Laura Portillo</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keijzers</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lim</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haelst</LastName><ForeName>Ingrid van</ForeName><Initials>IV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sombogaard</LastName><ForeName>Ferdi</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Roland van den</ForeName><Initials>RVD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutkourt</LastName><ForeName>Firdaouss</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemper</LastName><ForeName>Marleen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slob</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kan</LastName><ForeName>Erikvan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helmers</LastName><ForeName>Annemiek Otten</ForeName><Initials>AO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filius</LastName><ForeName>Margreet</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hemminga</LastName><ForeName>Wietske</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghazarian</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilarius</LastName><ForeName>Doranne</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kappers</LastName><ForeName>Mariette</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etten</LastName><ForeName>Ronald van</ForeName><Initials>RV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onzenoort</LastName><ForeName>Hein van</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wijngaarden</LastName><ForeName>Peter van</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diepstraten</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roelofsen</LastName><ForeName>Eveline</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meuwese</LastName><ForeName>Edmé Roobol</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wierenga</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graaf</LastName><ForeName>Ingrid Hoogendoorn de</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdonk</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ebbens</LastName><ForeName>Marieke</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendriksen</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linden</LastName><ForeName>Paul van der</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crommentuijn</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wit</LastName><ForeName>Hugo de</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guda</LastName><ForeName>Kaylen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dijk</LastName><ForeName>Suzanne van</ForeName><Initials>SV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosch</LastName><ForeName>Tessa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krens</LastName><ForeName>Lisanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slijfer</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurkens</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deben</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ezinga</LastName><ForeName>Marieke</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieuwkoop</LastName><ForeName>Kees van</ForeName><Initials>KV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Visser</LastName><ForeName>Loes</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boemaars</LastName><ForeName>Ebbie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maat</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derijks</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janssen</LastName><ForeName>Paddy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulsink</LastName><ForeName>Arjan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horst</LastName><ForeName>Peter Ter</ForeName><Initials>PT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleming</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodfellow</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanley</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoppelaar</LastName><ForeName>Francine de</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32587077</ArticleId><ArticleId IdType="pii">ejhpharm-2020-002329</ArticleId><ArticleId IdType="doi">10.1136/ejhpharm-2020-002329</ArticleId><ArticleId IdType="pmc">PMC7335622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacol Res. 2016 May;107:154-162</Citation><ArticleIdList><ArticleId IdType="pubmed">26995300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2020 Jun;75(6):1382-1385</Citation><ArticleIdList><ArticleId IdType="pubmed">32208987</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cardiol. 2020 May;17(5):259-260</Citation><ArticleIdList><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2005 Aug 30;173(5):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16129869</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Cell Cardiol. 2016 Aug;97:180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">27210827</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1801-1803</Citation><ArticleIdList><ArticleId IdType="pubmed">32196087</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2019 Oct;71(4):539-570</Citation><ArticleIdList><ArticleId IdType="pubmed">31537750</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Mar 27;367(6485):1444-1448</Citation><ArticleIdList><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 2020 Jun;38(6):1196-1197</Citation><ArticleIdList><ArticleId IdType="pubmed">32371817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2005 Nov;68(5):2189-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16221218</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Res. 2020 Mar 4;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32129518</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation><ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000108 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000108 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32587077
|texte= COvid MEdicaTion (COMET) study: protocol for a cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32587077" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |